Sanofi’s Promising Phase 3 Study on Amlitelimab for Atopic Dermatitis

Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

Sanofi is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of amlitelimab monotherapy in treating moderate-to-severe atopic dermatitis in individuals aged 12 and older. This study, titled A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis, aims to provide a new treatment option for patients whose conditions are not adequately managed by existing topical therapies.

The study is testing amlitelimab, administered via subcutaneous injection, against a placebo. Amlitelimab is designed to offer relief for those suffering from atopic dermatitis by targeting specific pathways involved in the disease.

This trial is interventional, with a randomized, parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.

The study began on November 8, 2023, with an estimated completion date not yet specified. The primary completion date is crucial as it marks when the primary data collection is finished, while the last update was submitted on August 7, 2025, indicating ongoing progress and adjustments.

The outcome of this study could significantly impact Sanofi’s market position, potentially boosting investor confidence and stock performance if results are favorable. It also places Sanofi in a competitive stance within the pharmaceutical industry, particularly in the dermatology sector.

The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.